Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: A summary of 480 cases

Annals of Surgery

Volumn 253, Issue 5, 2011, Pages 934-939

  Becker, Karen ^a   Langer, Rupert ^a   Reim, Daniel ^a   Novotny, Alexander ^a   Meyer Zum Buschenfelde, Christian ^a   Engel, Jutta ^b   Friess, Helmut ^a   Hofler, Heinz ^a,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINATE CALCIUM; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; STOMACH ADENOCARCINOMA; TUMOR REGRESSION;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GASTRECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR BURDEN; YOUNG ADULT;

EID: 79954462482     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e318216f449     Document Type: Article

References (28)

1. Ajani JA, Walsh G, Komaki R, et al. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer. 2004;100(11):2347-2354. (Pubitemid 38657881)
2. Brenner B, Shah MA, Karpeh MS, et al. A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridineleucovorin in patients with locally advanced gastric cancer. Ann Oncol. 2006;17(9):1404-1411. (Pubitemid 44403435)
3. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11-20.
4. Fujitani K, Ajani JA, Crane CH, et al. Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junction. Ann Surg Oncol. 2007;14(4):1305-1311. (Pubitemid 46536829)
5. Ott K, Sendler A, Becker K, et al. Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer. 2003;6(3):159-167. (Pubitemid 37221566)
6. Lordick F, Stein HJ, Peschel C, et al.Neoadjuvant therapy for oesophagogastric cancer. Br J Surg. 2004;91(5):540-551. (Pubitemid 38624660)
7. Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98(7):1521-1530. (Pubitemid 37151509)
8. Napieralski R, Ott K, Kremer M, et al. Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvanttreated gastric cancer patients. Clin Cancer Res. 2005;11(8):3025-3031. (Pubitemid 40525208)
9. Ott K, Lordick F, Becker K, et al. Glutathione-S-transferase P1, T1 and M1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer: GSTM1-present genotype is associated with better prognosis in completely resected patients. Int J Colorectal Dis. 2008;23(8): 773-782.
10. Schuhmacher CP, Fink U, Becker K, et al. Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Closing results after 5 years of follow-up. Cancer. 2001;91(5): 918-927.
11. Sobin L, Wittekind Ch, eds. UICC. TNM classification of malignant tumours. New York: John Wiley & Sons, 2002.
12. Boige V, Pignon J, Saint-Aubert B, et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07- FFCD 9703 trial. J Clin Oncol (Meeting Abstracts). 2007; 25(18 suppl): 4510.
13. Langer R, Ott K, Feith M, et al. Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. Mod Pathol. 2009;22(12):1555-1563.
14. Swisher SG, Hofstetter W, Wu TT, et al. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg. 2005;241(5):810-817; discussion 817-820.
15. Brucher BL, Becker K, Lordick F, et al. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer. 2006;106(10):2119-2127. (Pubitemid 43673232)
16. Rosenberg R, Nekarda H, Zimmermann F, et al. Histopathological response after preoperative radiochemotherapy in rectal carcinoma is associated with improved overall survival. J Surg Oncol. 2008;97(1):8-13.
17. Ajani JA, Mansfield PF, Crane CH, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol. 2005;23(6): 1237-1244. (Pubitemid 46202281)
18. Chang F, Deere H, Mahadeva U, et al. Histopathologic examination and reporting of esophageal carcinomas following preoperative neoadjuvant therapy: practical guidelines and current issues. Am J Clin Pathol. 2008;129(2): 252-262. (Pubitemid 352029316)
19. Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103(7):1347-1355. (Pubitemid 40410728)
20. Fontana MG, La Pinta M, Moneghini D, et al. Prognostic value of Goseki histological classification in adenocarcinoma of the cardia. Br J Cancer. 2003;88(3):401-405. (Pubitemid 36308151)
21. Luebke T, Baldus SE, Grass G, et al. Histological grading in gastric cancer by Ming classification: correlation with histopathological subtypes, metastasis, and prognosis. World J Surg. 2005;29(11):1422-1427; discussion 1428.
22. Fareed KR, Kaye P, Soomro IN, et al. Biomarkers of response to therapy in oesophago-gastric cancer. Gut. 2009;58(1):127-143.
23. Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8(9):797-805. (Pubitemid 47308659)
24. Ott K, Herrmann K, Lordick F, et al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res. 2008;14(7):2012-2018. (Pubitemid 351551110)
25. Hede K. Gastric cancer: trastuzumab trial results spur search for other targets. J Natl Cancer Inst. 2009;101(19):1306-1307.
26. Vecchione L, Orditura M, Ciardiello F, et al. Novel investigational drugs for gastric cancer. Expert Opin Investig Drugs. 2009;18(7):945-955.
27. Jackson C, CunninghamD,Oliveira J.On behalf of the EGWG. Gastric cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(suppl 4):iv34-36.
28. Gallego-Plazas J, Menarguez-Pina F, Martinez-Banaclocha N, et al. Early distant relapse after optimal local control in locally advanced rectal cancer. Int Semin Surg Oncol. 2008;5:18.